MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 05-14-2026
AstraZeneca PLC Revenue 2011-2026 | AZN
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue AstraZeneca PLC
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 58.7 B | 54.1 B | 45.8 B | 44.4 B | 37.4 B | 26.6 B | 24.4 B | 22.1 B | 22.5 B | 23 B | 24.7 B | 26.1 B | 25.7 B | 28 B | 33.6 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 58.7 B | 22.1 B | 33.1 B |
Quarterly Revenue AstraZeneca PLC
| 2025-Q4 | 2025-Q2 | 2024-Q4 | 2024-Q2 | 2023-Q4 | 2023-Q2 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 58.7 B | 14.5 B | 54.1 B | 12.9 B | 45.8 B | 11.4 B | - | - | - | - | - | - | 8.22 B | - | - | - | 6.28 B | - | - | - | 5.82 B | - | - | - | 5.16 B | - | - | - | 5.05 B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 58.7 B | 5.05 B | 20.7 B |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Biotechnology industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
257 K | - | 5743.5 % | $ 69.7 M |  Canada |
 |
MorphoSys AG
MOR
|
238 M | - | 2.43 % | $ 254 M |  Germany |
 |
Happiness Biotech Group Limited
HAPP
|
71.5 K | - | 1.35 % | $ 17.8 M |  China |
 |
AgeX Therapeutics
AGE
|
130 K | - | -10.17 % | $ 12.2 K |  USA |
 |
I-Mab
IMAB
|
88 M | - | - | $ 866 M | China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
6.07 B | - | - | $ 40.3 B | USA |
 |
Coherus BioSciences
CHRS
|
42.2 M | $ 1.63 | - | $ 191 M | USA |
 |
Genfit SA
GNFT
|
70.9 M | - | 2.54 % | $ 160 B |  France |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
12.1 K | - | -1.52 % | $ 24.7 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
82 M | $ 7.83 | - | $ 214 M |  Israel |
 |
Midatech Pharma plc
MTP
|
381 K | - | -18.52 % | $ 27.3 M |  Britain |
 |
AbCellera Biologics
ABCL
|
75.1 M | $ 4.4 | - | $ 1.31 B | Canada |
 |
Amphastar Pharmaceuticals
AMPH
|
720 M | $ 17.3 | - | $ 809 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
75.4 M | $ 1.59 | - | $ 423 M | Britain |
 |
Институт стволовых клеток человека
ISKJ
|
1.08 B | - | - | - |  Russia |
 |
BioNTech SE
BNTX
|
482 M | $ 91.99 | - | $ 22.2 B | Germany |
 |
Compugen Ltd.
CGEN
|
6 M | $ 3.03 | - | $ 283 M | Israel |
 |
Advaxis
ADXS
|
13 K | - | -9.65 % | $ 45.9 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
405 K | $ 3.49 | - | $ 5.75 M | Israel |
 |
Aeterna Zentaris
AEZS
|
7.5 M | - | 5.93 % | $ 314 M | Canada |
 |
Aeglea BioTherapeutics
AGLE
|
886 K | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
48.9 M | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
325 K | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
123 M | - | 1.93 % | $ 17.4 M | USA |
 |
Aptinyx
APTX
|
1 M | - | -39.0 % | $ 4.57 M | USA |
 |
Albireo Pharma
ALBO
|
40.6 M | - | -0.23 % | $ 916 M | USA |
 |
AlloVir
ALVR
|
165 K | - | 4.14 % | $ 49.1 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
376 M | $ 21.57 | - | $ 2.74 B | USA |
 |
Fennec Pharmaceuticals
FENC
|
44.6 M | $ 9.24 | - | $ 264 M | USA |
 |
Esperion Therapeutics
ESPR
|
403 M | $ 3.12 | - | $ 649 M | USA |
 |
Eton Pharmaceuticals
ETON
|
80 M | $ 29.96 | - | $ 806 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
1.16 M | - | -11.43 % | $ 502 K | USA |
 |
Exelixis
EXEL
|
2.32 B | $ 51.1 | - | $ 13.9 B | USA |
 |
Alpine Immune Sciences
ALPN
|
30.1 M | - | - | $ 2.17 B | USA |
 |
Applied Therapeutics
APLT
|
9.99 M | - | - | $ 8.42 M | USA |
 |
Aravive
ARAV
|
9.14 M | - | -13.39 % | $ 1.45 M | USA |